Evaluation of intravenous amoxicillin-clavulanate use in two Canadian hospitals.
Maggie WongSangita MalhotraKevin AfraPublished in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2024)
We describe our experience with intravenous amoxicillin-clavulanate, which is new to the Canadian market. The majority of patients were successfully de-escalated from piperacillin-tazobactam or a carbapenem for respiratory infections or skin and soft tissue infections. Intravenous amoxicillin-clavulanate provides a good alternative in an era of rising Pseudomonas aeruginosa resistance.
Keyphrases
- soft tissue
- pseudomonas aeruginosa
- high dose
- end stage renal disease
- acinetobacter baumannii
- ejection fraction
- newly diagnosed
- healthcare
- cystic fibrosis
- gram negative
- peritoneal dialysis
- prognostic factors
- health insurance
- biofilm formation
- klebsiella pneumoniae
- staphylococcus aureus
- drug resistant
- escherichia coli
- patient reported outcomes